

Roche in Cancer Care

The Roche Group, including its members Genentech in the United States and Chugai in Japan, is the world's leading provider of cancer care products, including anti-cancer treatments, supportive care products and diagnostics. The Group's anticancer medicines include an unprecedented five innovative cancer products proven to provide survival benefit in six different major tumor indications: Avastin® (bevacizumab), Herceptin® (trastuzumab), Xeloda® (capecitabine), MabThera® (rituximab) and Tarceva® (erlotinib).

In addition to its innovative portfolio of cancer medicines, Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future. With a broad portfolio of tumour markers for prostate, colorectal, liver, ovarian, breast, stomach, pancreas and lung cancer, as well as a range of molecular oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics.

Additional information is available on the Internet at www.roche.com

To access video clips, of broadcast standard, free of charge, please go to: www.thenewsmarket.com.